{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-066676","form_type":"8-K","ticker":"GRML","cik":"0001907223","company_name":"Greenland Mines Ltd","filed_at":"2025-07-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.569295+00:00","generated_at":"2026-05-18T04:34:02.274987+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Klotho Neurosciences enters exclusive global gene therapy license with AAVnerGene","bullets":["Exclusive global rights to AAVnerGene's AAVone platform for three gene therapy programs: KLTO-101, KLTO-202, KLTO-303.","Initial license fees: $250,000 (first product) to $500,000 (third product); plus 2% royalty on revenue.","Targets Alzheimer's, Parkinson's, ALS, motor neuron diseases, and aging-related pathologies.","CEO cites faster, cheaper manufacturing with higher purity and lower toxicity via AAVone and ATHENA platforms.","Partnership aims to accelerate clinical development and reduce high drug price/dose-related toxicity."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-066676","json":"https://secwatch.observer/filing/0001213900-25-066676.json","markdown":"https://secwatch.observer/filing/0001213900-25-066676.md","text":"https://secwatch.observer/filing/0001213900-25-066676.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907223/000121390025066676/0001213900-25-066676-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907223/000121390025066676/ea0249890-8k_klotho.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T04:34:02.274987+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}